UF研究人员发现了一种直肠分子,在小鼠体内推动肺癌免疫疗法,抗药性病例中的肿瘤缩小50%。 UF researchers found a gut-derived molecule that boosts lung cancer immunotherapy in mice, shrinking tumors by 50% in resistant cases.

UF Health的研究人员发现了Bac429, 一种直肠微生物衍生分子,它加强了小鼠的肺癌免疫疗法,使抗治疗病例的肿瘤增长减少了50%。 Researchers at UF Health have discovered Bac429, a gut microbiome-derived molecule, that enhances lung cancer immunotherapy in mice, reducing tumor growth by 50% in treatment-resistant cases. 帮助“冷”肿瘤“热”转变, 增强免疫反应。 The compound, identified from beneficial bacteria in patients who responded to therapy, helps turn "cold" tumors "hot" by boosting immune response. 它可以与现有的免疫疗法一起使用,而不增加毒性,提供一种非侵入性方法来改善患者的治疗结果。 It may be used alongside existing immunotherapies without added toxicity, offering a non-invasive way to improve patient outcomes. 这些研究结果发表在《细胞报告医学》中,导致专利申请和Bebi治疗学公司的创建,并有可能在肺癌之外进行应用。 The findings, published in Cell Reports Medicine, have led to patent applications and the creation of Bebi Therapeutics Inc., with potential applications beyond lung cancer.